Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.

Guggenheim's Emerging Outlook: Biotech Summit
Format: Fireside Chat
Date: Thursday, February 12, 2026
Time: 3:00 – 3:25 p.m. ET

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Format: Fireside Chat
Date: Wednesday, February 25, 2026
Time: 1:20 – 1:50 p.m. ET

Leerink Global Healthcare Conference
Format: Fireside Chat
Date: Monday, March 9, 2026
Time: 2:20 – 2:50 p.m. ET

The live webcasts will be accessible via the “Investors & Media” section of the Climb Bio website. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.

About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy. For more information, please visit climbbio.com. 

Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
[email protected]

You May Also Be Interested In

• ITF Group Named a 2026 Top Workplace by the St. Louis Post-Dispatch for the Third Consecutive Year
• Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
• Circana’s 2026/2027 Global Food and Beverage Outlook Predicts Slow-to-Moderate Growth as Market Enters Period of Rationalization